These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
372 related articles for article (PubMed ID: 25651238)
1. Multiple BRAF Wild-Type Melanomas During Dabrafenib Treatment for Metastatic BRAF-Mutant Melanoma. Carrera C; Puig-Butillè JA; Tell-Marti G; García A; Badenas C; Alós L; Puig S; Malvehy J JAMA Dermatol; 2015 May; 151(5):544-8. PubMed ID: 25651238 [TBL] [Abstract][Full Text] [Related]
2. Dabrafenib in an elderly patient with metastatic melanoma and BRAF V600R mutation: a case report. Casadevall D; Vidal J; Gallardo F; Zuccarino F; Arumí-Uría M; Dalmases A; Bellosillo B; Montagut C J Med Case Rep; 2016 Jun; 10(1):158. PubMed ID: 27255157 [TBL] [Abstract][Full Text] [Related]
4. Dabrafenib therapy for advanced melanoma. Trinh VA; Davis JE; Anderson JE; Kim KB Ann Pharmacother; 2014 Apr; 48(4):519-29. PubMed ID: 24259661 [TBL] [Abstract][Full Text] [Related]
5. BRAFV600E mutation status of involuting and stable nevi in dabrafenib therapy with or without trametinib. McClenahan P; Lin LL; Tan JM; Flewell-Smith R; Schaider H; Jagirdar K; Atkinson V; Lambie D; Prow TW; Sturm RA; Soyer HP JAMA Dermatol; 2014 Oct; 150(10):1079-82. PubMed ID: 24695877 [TBL] [Abstract][Full Text] [Related]
6. Dabrafenib and trametinib, alone and in combination for BRAF-mutant metastatic melanoma. Menzies AM; Long GV Clin Cancer Res; 2014 Apr; 20(8):2035-43. PubMed ID: 24583796 [TBL] [Abstract][Full Text] [Related]
7. The somatic affairs of BRAF: tailored therapies for advanced malignant melanoma and orphan non-V600E (V600R-M) mutations. Ponti G; Pellacani G; Tomasi A; Gelsomino F; Spallanzani A; Depenni R; Al Jalbout S; Simi L; Garagnani L; Borsari S; Conti A; Ruini C; Fontana A; Luppi G J Clin Pathol; 2013 May; 66(5):441-5. PubMed ID: 23463675 [TBL] [Abstract][Full Text] [Related]
8. Panniculitis with arthralgia in patients with melanoma treated with selective BRAF inhibitors and its management. Zimmer L; Livingstone E; Hillen U; Dömkes S; Becker A; Schadendorf D Arch Dermatol; 2012 Mar; 148(3):357-61. PubMed ID: 22250191 [TBL] [Abstract][Full Text] [Related]
9. Clinical development of dabrafenib in BRAF mutant melanoma and other malignancies. Gibney GT; Zager JS Expert Opin Drug Metab Toxicol; 2013 Jul; 9(7):893-9. PubMed ID: 23621583 [TBL] [Abstract][Full Text] [Related]
10. Complete Cytologic Remission of V600E BRAF-Mutant Melanoma-Associated Leptomeningeal Carcinomatosis Upon Treatment With Dabrafenib. Wilgenhof S; Neyns B J Clin Oncol; 2015 Oct; 33(28):e109-11. PubMed ID: 24733801 [No Abstract] [Full Text] [Related]
12. Dabrafenib and its potential for the treatment of metastatic melanoma. Menzies AM; Long GV; Murali R Drug Des Devel Ther; 2012; 6():391-405. PubMed ID: 23251089 [TBL] [Abstract][Full Text] [Related]
14. Cutaneous adverse effects of BRAF inhibitors in metastatic malignant melanoma, a prospective study in 20 patients. Vanneste L; Wolter P; Van den Oord JJ; Stas M; Garmyn M J Eur Acad Dermatol Venereol; 2015 Jan; 29(1):61-8. PubMed ID: 24661317 [TBL] [Abstract][Full Text] [Related]
15. Efficacy and Safety of Nivolumab in Patients With BRAF V600 Mutant and BRAF Wild-Type Advanced Melanoma: A Pooled Analysis of 4 Clinical Trials. Larkin J; Lao CD; Urba WJ; McDermott DF; Horak C; Jiang J; Wolchok JD JAMA Oncol; 2015 Jul; 1(4):433-40. PubMed ID: 26181250 [TBL] [Abstract][Full Text] [Related]
16. Overwhelming response to Dabrafenib in a patient with double BRAF mutation (V600E; V600M) metastatic malignant melanoma. Ponti G; Tomasi A; Pellacani G J Hematol Oncol; 2012 Oct; 5():60. PubMed ID: 23031422 [TBL] [Abstract][Full Text] [Related]
17. Phase II trial (BREAK-2) of the BRAF inhibitor dabrafenib (GSK2118436) in patients with metastatic melanoma. Ascierto PA; Minor D; Ribas A; Lebbe C; O'Hagan A; Arya N; Guckert M; Schadendorf D; Kefford RF; Grob JJ; Hamid O; Amaravadi R; Simeone E; Wilhelm T; Kim KB; Long GV; Martin AM; Mazumdar J; Goodman VL; Trefzer U J Clin Oncol; 2013 Sep; 31(26):3205-11. PubMed ID: 23918947 [TBL] [Abstract][Full Text] [Related]
18. Cutaneous manifestations of dabrafenib (GSK2118436): a selective inhibitor of mutant BRAF in patients with metastatic melanoma. Anforth RM; Blumetti TC; Kefford RF; Sharma R; Scolyer RA; Kossard S; Long GV; Fernandez-Peñas P Br J Dermatol; 2012 Nov; 167(5):1153-60. PubMed ID: 22804352 [TBL] [Abstract][Full Text] [Related]
19. Overcoming metastatic melanoma with BRAF inhibitors. Hong S; Hong S; Han SB Arch Pharm Res; 2011 May; 34(5):699-701. PubMed ID: 21656352 [TBL] [Abstract][Full Text] [Related]
20. Targeted therapies for cutaneous melanoma. Kee D; McArthur G Hematol Oncol Clin North Am; 2014 Jun; 28(3):491-505. PubMed ID: 24880943 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]